News

Novo Nordisk faces potential layoffs after a period of rapid expansion fueled by the success of Wegovy. The company's workforce nearly doubled in five years, but slowing sales and increased ...
As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff ...
The pharma giant has almost doubled the size of its workforce over the last five years but is now looking to tighten cost ...
A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits totaling more than $2 billion circulated online in August 2025.
Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from the head of ...
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...
GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...
Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...
The CDMO will be cutting 350 jobs at its Baltimore gene therapy site after a major client’s demand shift, less than a year after Novo Holdings’ $16.5 billion acquisition.
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.